Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

China flag China · Delayed Price · Currency is CNY
18.64
-0.10 (-0.53%)
At close: Dec 5, 2025
-20.27%
Market Cap 30.42B
Revenue (ttm) 24.18B
Net Income (ttm) 1.43B
Shares Out 1.63B
EPS (ttm) 0.87
PE Ratio 21.33
Forward PE 14.23
Dividend 0.47 (2.51%)
Ex-Dividend Date Aug 19, 2025
Volume 14,750,980
Average Volume 17,619,450
Open 18.70
Previous Close 18.74
Day's Range 18.46 - 18.70
52-Week Range 18.33 - 25.90
Beta 0.47
RSI 28.52
Earnings Date Apr 7, 2026

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec... [Read more]

Sector Healthcare
Founded 1988
Employees 17,650
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 600079
Full Company Profile

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.

Financial Statements

News

There is no news available yet.